1912-24-9 MXWJVTOOROXGIU-UHFFFAOYSA-N MXWJVTOOROXGIU-UHFFFAOYSA-N Atrazine 1,3,5-Triazine-2,4-diamine, 6-chloro-N-ethyl-N'-(1-methylethyl)- 1,3,5-Triazine-2,4-diamine, 6-chloro-N2-ethyl-N4-(1-methylethyl)- 1-Chloro-3-ethylamino-5-isopropylamino-2,4,6-triazine 2-Chloro-4-(ethylamino)-6-(2-propylamino)-s-triazine 2-Chloro-4-(ethylamino)-6-(isopropylamino)-s-triazine 2-Chloro-4-(ethylamino)-6-(isopropylamino)triazine 2-Chloro-4-ethylamineisopropylamine-s-triazine 2-Chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine 2-Chloro-4-ethylamino-6-isopropylamino-s-triazine 2-Ethylamino-4-isopropylamino-6-chloro-s-triazine 6-Chloro-4-(ethylamino)-2-(isopropylamino)-s-triazine 6-Chloro-N-ethyl-N'-(1-methylethyl)-1,3,5-triazine-2,4-diamine AAtrex Nine-O Akticon Aktikon Aktikon PK Aktinit A Aktinit PK Argezin Atragranz Atranex Atranex 80WP Atraphyt Atrataf Atrazin atrazina Azoprim Chromozin Farmozine Gesamprim Gesaprim Gesaprim 50 Gesaprim 500 Gesaprim L Herbatoxol Hungazin Hungazin PK NSC 163046 Nu-Trazine Oleogesaprim Oleogesaprim 200 Primatol A Primoleo Radazin Radazin T s-Triazine, 2-chloro-4-(ethylamino)-6-(isopropylamino)- Triazine A 1294 Zealin L Zeazine DTXSID9020112 D007987 MESH Gonadotropin Releasing Hormone CHEBI:81568 CHEBI Luteinizing hormone CHEBI:50114 CHEBI estrogen PR:000013246 PR prolactin D000236 MESH Adenoma D002277 MESH Carcinoma GO:0046879 GO hormone secretion MP:0001928 MP abnormal ovulation GO:0060209 GO estrus MP:0000630 MP mammary gland hyperplasia MP:0010307 MP abnormal tumor latency 2 WIKI decreased 9 WIKI disrupted 5 WIKI delayed 1 WIKI increased atrazine 2016-11-29T18:42:27 2016-11-29T18:42:27 10116 NCBI SD rat Decreased, GnRH pulsatility/release in hypothalamus Cellular CL:0011111 CL gonadotropin releasing neuron AOPWiki 2016-11-29T18:41:29 2017-09-16T10:17:11 Decreased, LH Surge from anterior pituitary Cellular AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 interruption, Ovulation Individual AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 prolonged, estrus Individual AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 Increased, circulating estrogen levels Organ AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 Increased, prolactin exposure Tissue AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 Hyperplasia, Mammary gland Tissue UBERON:0001911 UBERON mammary gland AOPWiki 2016-11-29T18:41:29 2017-09-16T10:17:11 Increased, Adenomas/carcinomas (mammary) Tissue UBERON:0001911 UBERON mammary gland AOPWiki 2016-11-29T18:41:29 2017-09-16T10:17:12 Increased, latency period Individual AOPWiki 2016-11-29T18:41:29 2016-12-03T16:37:53 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b4302659828> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b430161f200> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42eb179018> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b42ea246d20> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b4308b94698> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00007b43085f6448> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00005eb89f11d5d0> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00005eb89ff82d78> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00005eb8a0580220> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 #<Reference::ActiveRecord_Associations_CollectionProxy:0x00005eb89f371250> AOPWiki 2016-11-29T18:41:36 2016-12-03T16:38:03 GnRH pulse disruption and mammary tumors. Arthur Author <p>Cancer AOP Workgroup. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)</p> BY-SA 1.29 1.0 <p>This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.</p> adjacent Not Specified High adjacent Not Specified High adjacent Not Specified High adjacent Not Specified Moderate adjacent Not Specified High non-adjacent Not Specified High non-adjacent Not Specified High non-adjacent Not Specified High non-adjacent Not Specified High non-adjacent Not Specified Moderate High Female High Not Specified <p>1. Meek, B., Renwick, A., Sonich-Mullin, C., and International Programme on Chemical, S. (2003a). Practical application of kinetic data in risk assessment--an IPCS initiative. Toxicology letters 138(1-2), 151-60.</p> <p>2. Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. (2003b). A framework for human relevance analysis of information on carcinogenic modes of action. Critical reviews in toxicology 33(6), 591-653, 10.1080/713608373.</p> <p>3. Rudmann, D., Cardiff, R., Chouinard, L., Goodman, D., Kuttler, K., Marxfeld, H., Molinolo, A., Treumann, S., Yoshizawa, K., Inhand Mammary, Z. s. P., and Clitoral Gland Organ Working, G. (2012). Proliferative and nonproliferative lesions of the rat and mouse mammary, Zymbal&#39;s, preputial, and clitoral glands. Toxicologic pathology 40(6 Suppl), 7S-39S, 10.1177/0192623312454242.</p> <p>4. Simpkins, J. W., Swenberg, J. A., Weiss, N., Brusick, D., Eldridge, J. C., Stevens, J. T., Handa, R. J., Hovey, R. C., Plant, T. M., Pastoor, T. P., and Breckenridge, C. B. (2011). Atrazine and breast cancer: a framework assessment of the toxicological and epidemiological evidence. Toxicological sciences&nbsp;: an official journal of the Society of Toxicology 123(2), 441-59, 10.1093/toxsci/kfr176.</p> <p>&nbsp;</p> AOPWiki 2016-11-29T18:41:17 2023-09-25T16:26:53